Monthly Archives: March 2012

Procter & Gamble (NYSE:PG) Expands With Teva According to Cincinatti.com, Consumer products company Procter & Gamble (NYSE:PG) announced that it will make a partnership agreement with Israeli pharmaceuticals firm Teva Pharmaceutical Ltd. to promote growth in its over-the-counter drug business … Continue reading →

Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer THE WOODLANDS, Texas, March 24, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Pablo Lapuerta, M.D. has … Continue reading →

NHS could publish prescription details for every GP practice Information on the 900million medicine prescriptions written out each year by England’s doctors, currently only seen by certain NHS staff, could be made available to the public online. A little-noticed section … Continue reading →

Research and Markets: 2011 Global Contract Manufacturing Market Analysis The global pharmaceutical contract manufacturing industry has registered strong growth during the past few years. The outsourcing of drugs manufacturing provides many advantages to the pharmaceutical companies, such as improved production … Continue reading →

Pharmaceutical company recalls high blood pressure drugs over dangerous labelling mix-up A pharmaceutical company has launched a voluntary recall of a drug which may have been mislabelled — with possible “life-threatening” consequences for patients with high blood pressure, says Health … Continue reading →

NHS trusts fight health secretary over ‘value-added’ drug pricing Plans by the health secretary, Andrew Lansley, to change the way the NHS agrees drug prices with pharmaceutical companies could leave the health service footing a large bill with no real … Continue reading →

Canada Drugs Online and Online Pharmacy Coupons Team-up for Best Drug Prices The most influential decision-making factor in purchasing is the cost. Businesses apply various strategies to lower down their material, machine, manpower and methodology costs. In lieu, Six Sigma … Continue reading →

Govt will protect interests of drug industry: Scindia NEW DELHI: Amid concerns expressed by the Indian industry, the government today said in Parliament that it will protect the interest of the domestic drug industry while finalising the free trade pact … Continue reading →

Pharma pricing must reflect wider values, progressive innovation: ABPI Value-based pricing (VBP) for medicines must reflect the burden of the disease being treated, the wider societal benefits which treatments bring and the fact that innovation is often gradual, the Association … Continue reading →

No proof of drug industry sway on WHO in pandemic: report Independent experts who examined the World Health Organisation’s handling of the H1N1 pandemic said on Thursday they had found no evidence of drug industry influence on the U.N. agency’s … Continue reading →